CompletedPhase 3NCT02859909
This Clinical Study is to Test Efficacy and Safety of BT595 in Chronic Primary Immune Thrombocytopenia (ITP)
Studying Autoimmune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Biotest
- Principal Investigator
- Judit Demeter, MD, PhD, DScSemmelweis University Medical School, First Department of Medicine, Department of Hematology, 1083 Budapest, Korányi S. u. 2/a, Hungary
- Intervention
- BT595(biological)
- Enrollment
- 34 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2016 – 2018
Study locations (22)
- Investigational site # 3597, Pleven, Bulgaria
- Investigational site # 3593, Plovdiv, Bulgaria
- Investigational site # 3598, Sofia, Bulgaria
- Investigational site # 3591, Sofia, Bulgaria
- Investigational site # 3596, Varna, Bulgaria
- Investigational site # 4202, Prague, Czechia
- Investigational site # 4901, Berlin, Germany
- Investigational Site #4902, München, Germany
- Investigational site # 3601, Budapest, Hungary
- Investigational site # 3604, Debrecen, Hungary
- Investigational site # 3607, Győr, Hungary
- Investigational site # 3602, Miskolc, Hungary
- Investigational site # 3603, Nyíregyháza, Hungary
- Investigational site # 3606, Pécs, Hungary
- Investigational site # 3811, Belgrade, Serbia
- +7 more locations on ClinicalTrials.gov
Collaborators
Syneos Health
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02859909 on ClinicalTrials.govOther trials for Autoimmune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07421167A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)Novartis Pharmaceuticals
- RECRUITINGPHASE3NCT07559331High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune ThrombocytopeniaShandong University
- RECRUITINGPHASE2NCT07362238Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07362199Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT07441525UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE2NCT07234019Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07297563Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07294365A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)Dizal Pharmaceuticals